Kamataki T - Search Results

1

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.

Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T. Fujieda M, et al. Among authors: kamataki t. Carcinogenesis. 2004 Dec;25(12):2451-8. doi: 10.1093/carcin/bgh258. Epub 2004 Aug 12. Carcinogenesis. 2004. PMID: 15308589

2

[Genetic polymorphisms of drug metabolizing enzymes].

Fujieda M, Yamazaki H, Kamataki T. Fujieda M, et al. Among authors: kamataki t. Gan To Kagaku Ryoho. 2002 May;29(5):663-8. Gan To Kagaku Ryoho. 2002. PMID: 12040668 Review. Japanese.

3

Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, Yokota J, Nemoto N, Sato K, Kamataki T. Ariyoshi N, et al. Among authors: kamataki t. Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):890-4. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12223434

4

Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, Honda G, Nakagawa K, Ishizaki T, Kamataki T. Kiyotani K, et al. Among authors: kamataki t. Pharmacogenetics. 2003 Nov;13(11):689-95. doi: 10.1097/00008571-200311000-00005. Pharmacogenetics. 2003. PMID: 14583682

5

High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.

Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T. Gyamfi MA, et al. Among authors: kamataki t. Eur J Clin Pharmacol. 2005 Feb;60(12):855-7. doi: 10.1007/s00228-004-0854-9. Epub 2005 Jan 20. Eur J Clin Pharmacol. 2005. PMID: 15660270

6

Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.

Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, Kamataki T. Kimura M, et al. Among authors: kamataki t. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24. Drug Metab Dispos. 2005. PMID: 15980104

7

Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.

Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H. Kamataki T, et al. Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10. doi: 10.1016/j.bbrc.2005.08.268. Epub 2005 Sep 15. Biochem Biophys Res Commun. 2005. PMID: 16176798 Review.

8

Cytochrome P450 2A6 phenotyping based on dietary caffeine intake in a Japanese population of non-smokers.

Kimura M, Shimizu M, Kiyotani K, Nakagawa K, Kamataki T, Yamazaki H. Kimura M, et al. Among authors: kamataki t. Drug Metab Lett. 2012 Jun 1;6(2):67-72. Drug Metab Lett. 2012. PMID: 22849705 Clinical Trial.

9

CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka.

Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, Sevgican F, Muthumala M, Kobayashi H, Kamataki T. Topcu Z, et al. Among authors: kamataki t. Carcinogenesis. 2002 Apr;23(4):595-8. doi: 10.1093/carcin/23.4.595. Carcinogenesis. 2002. PMID: 11960911

10

CYP2A6 gene deletion reduces susceptibility to lung cancer.

Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N, Kamataki T. Miyamoto M, et al. Among authors: kamataki t. Biochem Biophys Res Commun. 1999 Aug 11;261(3):658-60. doi: 10.1006/bbrc.1999.1089. Biochem Biophys Res Commun. 1999. PMID: 10441482

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

413 results

Search Page

Filters